[1] Cotran, Kumar, Collins “Le basi fisiopatologiche delle malattie” Ed. Piccin 2000;
[2] Rugarli, Medicina Interna Sistematica, Elsevier 2010;
[3] S. Ardizzone, A.Cassinotti, G. Bianchi Porro “Terapia della colite ulcerosa lieve-moderata e severa” in Terapia delle Malattie Infiammatorie Croniche Intestinali, Immagine Ed.2009;
[4] N. Fusetti, L. Simone, V. Cifalà, A. Carella, A. Zelante “La terapia di mantenimento della rettocolite ulcerosa” in Terapia delle Malattie Infiammatorie Croniche Intestinali, Immagine Ed.2009;
[5] M. Campieri, P.Gionchetti, F. Rizzello, R. Tambasco, G. Straforini, R. Brugnera “La terapia delle IBD: passato, presente e futuro” in Terapia delle Malattie Infiammatorie Croniche Intestinali, Immagine Ed.2009;
[6] A.De Pascale, G. Garofalo, M.Perna, S. Priola, C. Fava “Contrast– enhanced ultrasonography in Crohn’s disease”, Abdominal Radiology, Vol.111, Num. 4, 539-550.
[7] S. Rovida, G. Fiorino, S. Danese “I molteplici ruoli patogenetici del microcircolo nelle malattie infiammatorie croniche intestinali” in IBD Year Book 2008
[8] Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P; ACCENT I Study Group. “Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial”; Lancet 2002 May 4;359(9317):1541-9;
[9] P. Rutgeerts, S. Vermeire, and G. Van Assche “Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?” Gut. 2007 April; 56(4): 453–455;
[10] Fabian Schnitzler, Herma Fidder, Marc Ferrante, Maja Noman Ingrid Arijs, Gert Van Assche, Ilse Hoffman, Kristel Van Steen, Séverine
Vermeire, Paul Rutgeerts “Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease" Inflammatory Bowel Diseases 15(9):1295–1301, September 2009;
[11] Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos
M, Stokkers P, Hommes D, Rutgeerts P, Vermeire S, D'Haens G; Belgian
Inflammatory Bowel Disease Research Group; North-Holland Gut Club. “Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease”.
[12] Vermeire S, Van Assche G, Rutgeerts P: “Review article: altering the natural history of Crohn’s disease – evidence for and against current therapies” Alimentary Pharmacology & Therapeutics, 25(1):pages 3–12, January 2007;
[13] Froslie K.F, Jahnsen J,.Moum BA et al ( I.B.S.E.N. Group). “Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort.” Gastroenterology 2007;133: 412–422;
[14] Scholmerich J.: Inflammatory Bowel Disease. Endoscopy. 2003;
35:164 – 170
[15] R. Sostegni, M. Daperno, N. Scaglione, A. Lavagna, R. Rocca & A. Pera “Review article: Crohn’s disease: monitoring disease activity”, Aliment Pharmacol Ther 2003; 17 (Suppl. 2): 11–17.
[16] E. Colombo, F. Bossa, V. Annese “Inquadramento diagnostico delle malattie infiammatorie croniche intestinali” in Terapia delle Malattie Infiammatorie Croniche Intestinali, Immagine Ed.2009;
[17] Costa F, Mumolo MG, Bellini M et al.: “Role of fecal calprotectin as non-invasive marker of intestinal inflammation” Dig. Liver Dis. 2003
[18] Rampton D.S., Shanahan F.:“Fast Facts: Malattie infiammatorie croniche dell'intestino”; Health Press 2010;
[19] Brahme F., Lindstrom C. “A comparative radiographic and pathological study of intestinal vaso-architecture in Crohn's disease and in ulcerative colitis”; Gut 1970;11:928-940;
[20] Wakefield, AJ, Sawyer, AM & Dhillon, AR.: “Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction.” Lancet. 1989; 2: 1057-62; [21] Amy K. Hara, Shayan Alam, Russell I. Heigh, Suryakanth R.Gurudu, Joseph G. Hentz, Jonathan A. Leighton “ Using CT Enterography to monitor Crohn’s Disease Activity:a preliminary study”; AJR 2008; 190:1512–1516;
[22] Solem, CA, Loftus EV , Tremaine W, et al. “Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease”; Inflammatory Bowel Dis. 2005 Aug;11(8): 707 - 12
[23] Bodily KD, Fletcher JD, Solem AC et al.: ”Crohn Disease: Mural attenuation and thickness at contrast-enhanced CT enterography— Correlation with endoscopic and histologic findings of inflammation.” Radiology, 2006;238:505 – 16;
[24] Groshar D, Bernstine H, Stern D. et al.: “PET/CT enterography in Crohn disease: correlation of disease activity on CTenterography with 18F-FDG uptake”; J.Nucl. Med. 2010 Jul;51(7):1009-14;
[25] Koh DM, Miao Y, Chinn RJS et al.: ”MR imaging evaluation of the activity of Crohn's Disease”; AJR December 2001 vol. 177 no. 6 1325- 1332 ;
[26] Röttgen R, Grandke T, Grieser C, Lehmkuhl L, Hamm B, Lüdemann: “Measurement of MRI enhancement kinetics for evaluation of inflammatory activity in Crohn's disease.”; Clin Imaging 2010 - 34(1):29-35 ;
[27] S. Giusti, L. Faggioni, E. Neri, E. Fruzzetti, L. Nardini, S. Marchi, C. Bartolozzi: “Dynamic MRI of the small bowel: usefulness of quantitative contrast-enhancement parameters and time–signal intensity curves for differentiating between active and inactive Crohn’s disease”; Abdom Imaging (2010) 35:646–653;
[28] Alois Hollerweger, Klaus Dirks, Kazimierz Szopinski: “Transabdominal ultrasound of the gastrointestinal tract” EFSUMB – European Course Book- 2011;
[29] Odd Helge Gilja, Barbara Braden, Fabio Piscaglia, Christoph F. Dietrich:”Functional ultrasound of the gastrointestinal tract” EFSUMB – European Course Book – 2011;
[30] G. Maconi, S. Bollani, and G. B. Porro: “Ultrasonographic detection of intestinal complications in Crohn's disease,” Digestive Diseases and Sciences, vol. 41, no. 8, pp. 1643–1648, 1996;
[31] G. Maconi, A. Di Sabatino, S. Ardizzone:”Prevalence and clinical significance of sonographic detection of enlarged regional lymph nodes in Crohn's disease. “Scand. J. Gastroenterol. 2005, 40(11):1328-33;
[32] Esteban JM, Maldonado L, Sanchiz V et al.:”Activity of Crohn's disease assessed by colour Doppler ultrasound analysis of the affected loops”. Eur. Radiol.2001;11(8):1423-8;
[33] SpalingerJ, Patriquin H, Miron MC et al.: “Doppler US in patients with Crohn Disease: vessel density in the diseased bowel reflects disease activity” Radiology, Dec 2000;217, 787-791.
[34] Drews BH, Barth TF, Haenle MM et al.: “Comparison of sonographically measured bowel wall vascularity, histology, and disease activity in Crohn’s disease” Eur. Radiol. 2009 Jun; 19(6):1379-1386 ;
[35] Lassau N.: “Evaluation of contrast-enhanced color Doppler
ultrasound for the quantification of angiogenesis in vivo.”;Invest
Radiol 2001; 36: 50-55
;
[36] Ophir et al. “Contrast agent in diagnostic ultrasound”. Ultrasound
Med Biol 1989; 15: 319-33
[37] Stephanie R.Wilson, Peter N. Burns: “Microbubble-enhanced US in Body Imaging: What Role?”; Radiology: Volume 257: Number 1—October 2010
[38] Horsthuis K, Bipat S, Bennink RJ, Stoker J. “Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies.” Radiology 2008; 247(1): 64–79 ;
[39] Sturm EJ, Cobben LP, Meijssen MA et al: “Detection of ileocecal Crohn’s disease using ultrasound as the primary imaging modality“; Eur. Radiol.2004;14:778-782;
[40] Fraquelli M, Colli A, Casazza G et al: “Role of US in detection of Crohn Disease: meta-analysis”; Radiology, 2005;236, 95-101.
[41] Hirche TO, Russler J, Schroeder O et al.: “The value of routinely performed ultrasonography in patients with Crohn disease.”; Scand J. Gastroenterol.2002 Oct;37(10):1178-83;
[42] Serra C. “CEUS Imaging modality in the assesment of intestinal bowel disease (IBD) – its usefulness in evaluating disease activity and treatment efficacy” in Contrast Enhanced Ultrasound (Canexion) 2010;
[43] Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez
M, Ochsenkühn T, Orchard T, Rogler G, Louis E, Kupcinskas L, Mantzaris
G, Travis S, Stange E; European Crohn's and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis.
J Crohns Colitis. 2010 Feb;4(1):7-27;
[44] Colombel J, Solem CA, Sandborn WJ: “Quantitative measurement and visual assessment of ileal Crohn’s disease activity by computed tomography enterography: correlation with endoscopic severity and C
reactive protein”; Gut 2006;55:1561-1567
[45] A. De Franco, M. Marzo, C. Felice, D.Pugliese,A. Di Veronica, L.Bonomo, A. Armuzzi, L.Guidi: “Ileal Crohn’s disease: CEUS determination of activity”; Abdom Imaging (2012);
[46] C. Girlich, E.M. Jung, I. Iesalnieks, A.G. Schreyer, N. Zorger, U. Strauch, D. Schacherer “Quantitative assessment of bowel wall vascularisation in Crohn's disease with contrast-enhanced
ultrasound and perfusion analysis”
2009;Clin.Hemorheol.Circul.Vol.43,141-148
[47] Girlich C.,Schacherer D. et al: “Comparison between a clinical activity index (Harvey–Bradshaw-Index), laboratory inflammation markers and quantitative assessment of bowel wall vascularization by contrast-enhanced ultrasound in Crohn's disease”; Eur.J.Radiol.